SHENZHEN, China, July 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - subsidiary, Mellow Hope signed an agreement with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China. This agreement / arrangement now sets the stage for Mellow Hope to be fully authorized to conduct the international marketing of Haemophilus influenza type b conjugate vaccine in the global market.
In other corporate news, the company plans on commencing the registration in Chile, Indonesia, Egypt, and Russia within this month with the brand name "MEVAC-Hib".
The company will provide further details as they become available.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved